Bio-Rad Laboratories Class A
384 hedge funds and large institutions have $4.63B invested in Bio-Rad Laboratories Class A in 2025 Q2 according to their latest regulatory filings, with 53 funds opening new positions, 115 increasing their positions, 168 reducing their positions, and 101 closing their positions.
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
1.78% more ownership
Funds ownership: 84.91% → 86.68% (+1.8%)
2% less capital invested
Capital invested by funds: $4.71B → $4.63B (-$81.7M)
12% less funds holding
Funds holding: 436 → 384 (-52)
32% less repeat investments, than reductions
Existing positions increased: 115 | Existing positions reduced: 168
48% less first-time investments, than exits
New positions opened: 53 | Existing positions closed: 101
67% less call options, than puts
Call options by funds: $2.94M | Put options by funds: $8.81M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Eagle Investment Management
New York
|
+$225M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$29M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$28.7M |
| 4 |
ICP
Ilex Capital Partners
London,
United Kingdom
|
+$27.1M |
| 5 |
SCM
Scopia Capital Management
New York
|
+$22.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VanEck Associates
New York
|
-$132M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$86.5M |
| 3 |
BlackRock
New York
|
-$61.2M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
-$28.7M |
| 5 |
State Street
Boston,
Massachusetts
|
-$26M |
BIO Hedge Fund Activity: Q2 2025 in Review
384 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q2 2025, worth a combined $4.63B — down 1.7% from $4.71B a quarter earlier.
Sellers outnumbered buyers: 101 funds closed out of BIO and 53 opened new positions — a net loss of 48 holders — while 168 trimmed existing stakes and 115 added.
The largest buyer was First Eagle Investment Management, adding an estimated $225M. The largest seller was VanEck Associates, cutting an estimated $132M.
- 384 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q2 2025, down from 436 in Q1 2025.
- Funds reported $4.63B of Bio-Rad Laboratories Class A stock for Q2 2025, down 1.7% quarter-over-quarter.
- 53 funds opened new Bio-Rad Laboratories Class A positions in Q2 2025 and 101 closed out, a net change of -48 holders.
- The largest Bio-Rad Laboratories Class A buyer in Q2 2025 was First Eagle Investment Management, an estimated $225M added.
- The largest Bio-Rad Laboratories Class A seller in Q2 2025 was VanEck Associates, an estimated $132M sold.
Based on aggregated 13F filings for Q2 2025.